Analysis of Accessibility to Anti-Tuberculosis Drugs in the Asia-Pacific Region between 2019 and 2022
Significant disparities in drug accessibility persist across the Asia-Pacific region. Achieving the WHO End Tuberculosis Strategy goals requires accelerating drug regulatory approvals, strengthening public-private collaboration, and sustained international support for resource-limited settings.
Authors
- Siyan Yi (ORCID: https://orcid.org/0000-0002-3045-5386)
- Zhongfei Pei
- Sok King Ong
- Ming Xu
- Chitin Hon
Institutions
- Macau University of Science and Technology (MO)
- Universiti Brunei Darussalam (BN)
- Peking University (CN)
- University of Macau (MO)
- National University Health System (SG)
- George Institute for Global Health (CN)
Publication Details
- Journal
- International Journal of Infectious Diseases
- Published
- 2026-03-01
- DOI
- https://doi.org/10.1016/j.ijid.2026.108586
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00